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A B S T R A C T   
We herein describe rapid and accurate clinical testing for COVID-19 by nicking and extension chain reaction 
system-based amplification (NESBA), an ultrasensitive version of NASBA. The primers to identify SARS-CoV-2 
viral RNA were designed to additionally contain the nicking recognition sequence at the 5′-end of conven-
tional NASBA primers, which would enable nicking enzyme-aided exponential amplification of T7 RNA 
promoter-containing double-stranded DNA (T7DNA). As a consequence of this substantially enhanced amplifi-
cation power, the NESBA technique was able to ultrasensitively detect SARS-CoV-2 genomic RNA (gRNA) down 
to 0.5 copies/μL (= 10 copies/reaction) for both envelope (E) and nucleocapsid (N) genes within 30 min under 
isothermal temperature (41 ◦C). When the NESBA was applied to test a large cohort of clinical samples (n = 98), 
the results fully agreed with those from qRT-PCR and showed the excellent accuracy by yielding 100% clinical 
sensitivity and specificity. By employing multiple molecular beacons with different fluorophore labels, the 
NESBA was further modulated to achieve multiplex molecular diagnostics, so that the E and N genes of SARS- 
CoV-2 gRNA were simultaneously assayed in one-pot. By offering the superior analytical performances over 
the current qRT-PCR, the isothermal NESBA technique could serve as very powerful platform technology to 
realize the point-of-care (POC) diagnosis for COVID-19.   
1. Introduction 
Since the outbreak of novel coronavirus disease 2019 (COVID-19) in 
December 2019, it has rapidly spread across the globe and was declared 
pandemic by the World Health Organization (WHO) on March 11th, 
2020 (Wang et al., 2020; Yan et al., 2020; Zhu et al., 2020). As of 21 
September 2021, the pandemic of COVID-19 has infected over 228 
millions and killed over four millions, unprecedently threatening human 
health and causing tremendous economic loss on the global community 
(World Health Organization, 2021). 
Without question, timely and aggressive testing is essential in order 
to effectively contain the spread of COVID-19. The current gold standard 
for COVID-19 testing is quantitative reverse transcription-polymerase 
chain reaction (qRT-PCR) in which the viral RNA of SARS-CoV-2 is 
first reverse transcribed into complementary DNA (cDNA) followed by 
the qPCR reaction using the cDNA template (Guo et al., 2020; Lu et al., 
2020; Tahamtan and Ardebili, 2020). This technique is highly sensitive 
and could identify the viral RNA even from the patients at the early stage 
before the onset of symptoms. However, it is relatively slow and requires 
costly and bulky instrument for precise temperature control and skilled 
personnel, which significantly restrict its use only to centralized clinics 
or laboratories and preclude prompt patient triage elsewhere (Cui and 
Zhou, 2020; Park et al., 2020; Zhu et al., 2020). 
In resource-limited settings where challenges with molecular di-
agnostics exist, direct antigen testing based on lateral flow immunoassay 
offers an alternative option for the diagnosis of COVID-19 (Sheridan, 
2020). This technique is very rapid, simple, and cost-effective, but can 
not very effectively diagnose the patients with low viral titers and may 
lead to false-negative results, due to low sensitivity (Liu and Rusling, 
2021; Mak et al., 2020). Therefore, the direct antigen testing is used only 
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for first screening where the qRT-PCR is not feasible and the qRT-PCR is 
normally recommended for the confirmation of COVID-19 cases (Hab-
ibzadeh et al., 2021; Lee et al., 2020; Peeling et al., 2021). 
To advance the molecular diagnostics and facilitate point-of-care 
(POC) molecular diagnostics in resource-limited settings, isothermal 
nucleic acid amplification methods such as nucleic acid sequence-based 
amplification (NASBA) (Compton, 1991), rolling circle amplification 
(RCA) (Lizardi et al., 1998), loop-mediated isothermal amplification 
(LAMP) (Notomi et al., 2000), nicking enzyme amplification reaction 
(NEAR) (Van Ness et al., 2003), and recombinase polymerase amplifi-
cation (RPA) (Piepenburg et al., 2006) and so on (Jia et al., 2010; Jung 
et al., 2010; Lee et al., 2020b; Song et al., 2021; Vincent et al., 2004) 
have emerged as a compelling alternative to the conventional 
thermocycling-based amplification method. Some of them have been 
successfully integrated with CRISPR/Cas system to develop ultrasensi-
tive strategies to identify SARS-CoV-2 viral RNA such as specific high 
sensitivity enzymatic reporter unlocking (SHERLOCK) and DNA endo-
nuclease targeted CRISPR trans reporter (DETECTR) (Broughton et al., 
2020; Chen et al., 2018; Kellner et al., 2019; Patchsung et al., 2020). 
Of these, NASBA is one of the most representative isothermal 
amplification strategies, which was designed to detect genomic RNA 
(gRNA) targets. In the NASBA reaction, target RNA is first reverse 
transcribed and its opposite strand is synthesized to produce T7 
promotor-containing double stranded DNA (T7DNA). T7 RNA poly-
merase (T7RP) then promotes the transcription from the T7 RNA pro-
moter region within the T7DNA, consequently producing numerous 
antisense RNA amplicons, which could produce fluorescent signal upon 
binding to a specific molecular beacon (MB) probe. The NASBA has been 
very intensively utilized to detect target RNA molecules under an 
isothermal condition but the key intermediate component of NASBA, 
T7DNA, is just produced linearly and not in an exponential manner and 
thus the final amplification efficiency is not sufficiently high enough to 
enable highly sensitive detection of target RNA. 
To overcome this limitation and advance the NASBA technique, we 
recently developed a novel isothermal nucleic acid amplification 
method, termed nicking and extension chain reaction system-based 
amplification (NESBA) (Ju et al., 2021). By incorporating the nicking 
recognition sequence to the primer set to enable the nicking enzyme 
(NE)-aided exponential amplification, the NESBA achieved remarkably 
high sensitivity under an isothermal condition, which significantly 
outperforms NASBA. In this work, we applied the NESBA technique to 
test a large cohort of clinical samples for target envelope (E) and 
nucleocapsid (N) genes of SARS-CoV-2 and successfully confirmed all 
the COVID-19 cases. 
2. Materials and methods 
2.1. Materials 
All DNA oligonucleotides used in this study were synthesized and 
purified with high performance liquid chromatography (HPLC) by Bio-
neer® (Daejeon, Korea). The sequences of the oligonucleotides are listed 
in Table S1. Nt.AlwI, 10 × NEBuffer™ 2.1 (100 mM Tris-HCl, pH 7.9, 
500 mM NaCl, 100 mM MgCl2, and 1 mg/ml BSA), ribonucleotide so-
lution mixture (rNTPs), deoxynucleotide solution mixture (dNTPs), 
DNase I (RNase-free) were purchased from New England Biolabs Inc. 
(Beverly, MA, USA). NASBA enzyme cocktail (Avian myeloblastosis 
virus reverse transcriptase (AMV RT), RNase H, and T7 RNA polymerase 
in high molecular weight sugar matrix), and 3 × NASBA reaction buffer 
(120 mM Tris-HCl, pH 8.5, 210 mM KCl, 36 mM MgCl2, 30 mM DTT, and 
45% DMSO) were purchased from Life Science Advanced Technologies 
Inc. (St Petersburg, FL, USA). The gRNAs of SARS-CoV-2 (BetaCoV/ 
Korea/KCDC03/2020), MERS-CoV, and HCoV-NL63 were provided by 
the National Culture Collection for Pathogens (NCCP, Cheongju, Korea), 
and those of HCoV-229E and HCoV-OC43 were purchased from the 
Korea Bank for Pathogenic Viruses (KBPV, Seoul, Korea). Plasmid 
controls and gBlock® gene fragments of E and N genes of SARS-CoV and 
HCoV-HKU-1 were purchased from Intergrated DNA Technologies Inc. 
(Coralville, IA, USA). Ultrapure DNase/RNase-free distilled water (DW) 
purchased from Bioneer® was used in all experiments. All other chem-
icals were of analytical grade and used without further purification. 
2.2. In vitro transcription (IVT) from the DNA templates 
For the production of RNA for E and N genes of SARS-CoV and HCoV- 
HKU-1 from DNA templates, the PCR mixture (20 μL) was prepared to 
contain 2 μL IVT primer set (10 μM each), 10 μL KAPA HiFi HotStart 
Ready Mix (2 ×) (KAPA Biosystems, MA, USA), and 104 copies/μL of 
plasmid controls or gBlock® gene fragments. The PCR was then per-
formed for 3 min at 95 ◦C, followed by 35 cycles of 20 s at 98 ◦C, 15 s at 
60 ◦C, and 30 s at 72 ◦C, and further incubation for 2 min at 72 ◦C. After 
the completion of the reaction, the PCR product was analyzed by 1% 
agarose gel electrophoresis and purified by using Wizard® SV Gel and 
PCR Clean-Up System (Promega, WI, USA), and applied to HiScribe™ T7 
High Yield T7 RNA synthesis mix (New England Biolabs Inc., MA, USA) 
with the recommended composition of T7 RNA polymerase mix, rNTPs, 
and reaction buffer. The IVT reaction mixture was incubated for 3 h at 
37 ◦C, followed by DNase I treatment for 30 min to prevent DNA 
contamination. Finally, the RNA product was purified by using Mon-
arch® RNA cleanup kit (New England Biolabs Inc., MA, USA) according 
to the manufacturer’s protocol. Its concentration was determined by 
using NanoDrop™ 1000 spectrophotometer (Thermo Fisher Scientific, 
MA, USA). 
2.3. The NESBA reaction procedure for SARS-CoV-2 detection 
Prior to the assay, 30 μM of gene-specific MB in 1 × NESBA reaction 
buffer (45 mM Tris-HCl (pH 8.5), 70 mM KCl, 25 mM NaCl, 17 mM 
MgCl2, 10 mM DTT, 15% DMSO, and 50 μg/mL BSA) was heated up to 
95 ◦C for 5 min followed by slow cooling down to 25 ◦C, and further 
incubated at 25 ◦C for 30 min. 
The solution for NESBA (20 μL) was prepared by mixing 2.8 μL rNTPs 
(25 mM each), 1.4 μL dNTPs (10 mM each), 1.4 μL NESBA primer set (20 
μM each), 0.2 μL MB (30 μM), 7.7 μL NESBA reaction buffer (2.6 ×), 5 μL 
NASBA enzyme cocktail (4 ×), 0.5 μL Nt.AlwI (10 U/μL), and 1 μL of 
viral RNA. The prepared solution was then incubated at 41 ◦C for 1 h and 
fluorescent signals from each MB were measured every 1 min by using 
CFX Connect™ Real-Time System (Bio-Rad, CA, USA). 
2.4. RT-PCR 
The reverse transcription (RT)-PCR was conducted on a C1000™ 
thermal cycler (Bio-rad, CA, USA) in a 20 μL solution containing 4 μL 
reaction buffer for RT (5 ×), 0.6 μL RevertAid RT (200 U/μL), 2 μL PCR 
reaction buffer (10 ×), 1.4 μL dNTPs (2.5 mM each), 1.4 μL primer set 
(20 μM each), 0.5 μL i-StarmaxII™ DNA polymerase (5 U/μL), and 1 μL 
gRNA solution. T7DNA (NESBA), T7DNA-1 (NESBA), T7DNA-2 
(NESBA), and T7DNA (NASBA) were produced by employing NESBA 
and NASBA primers (T7DNA (NESBA): NESBA primer set, T7DNA-1 
(NESBA): NESBA forward primer and NASBA reverse primer, T7DNA- 
2 (NESBA): NASBA forward primer and NEBSA reverse primer, 
T7DNA (NASBA): NASBA primer set). RT was first carried out for 30 min 
at 50 ◦C and the PCR was performed for 10 min at 95 ◦C, followed by 35 
cycles of 30 s at 95 ◦C, 45 s at 50 ◦C, and 60 s at 72 ◦C, and further 
incubation for 5 min at 72 ◦C. After the completion of the reaction, the 
RT-PCR products were analyzed by agarose gel electrophoresis. The RT- 
PCR products were also purified from the product solution by using a 
Wizard® SV Gel and PCR Clean-Up System (Promega, WI, USA), and 
their concentrations were determined by using NanoDrop™ 1000 
spectrophotometer (Thermo Fisher Scientific, MA, USA). The purified 
RT-PCR products were used as the markers on lane M1~M4. 
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2.5. Gel electrophoresis analysis 
For agarose gel electrophoresis, a 5 μL aliquot of the reaction solution 
was resolved on 2% agarose gel containing EtBr at a constant voltage of 
135 V for 45 min using 1 × TBE as the running buffer. Gels were scanned 
using UV transilluminator (Bio-rad, CA, USA). 
2.6. Clinical sample testing with NESBA 
A total of 98 clinical samples including nasopharyngeal swab and 
sputum were collected from individuals with suspected SARS-CoV-2 
infection and placed into the universal transport medium (UTM) 
(Asanpharm, Seoul, Korea) by Severance hospital (IRB approval num-
ber: 4-2020-0465; Seoul, Korea). Severance hospital was approved by 
Korea Centers for Disease Control and Prevention (KCDC) as a biosafety 
level-3 (BL-3) facility in accordance with institutional biosafety re-
quirements. The gRNAs of the clinical samples were extracted by using 
AdvanSure™ Nucleic Acid R kit (LG chem, Seoul, Korea) according to 
the manufacturer’s protocol. The gRNAs were then assayed with the 
NESBA and the results were compared with those from qRT-PCR to 
verify its clinical applicability. 
2.7. The qRT-PCR procedure for clinical sample analysis 
The qRT-PCR was set up and carried out according to the manufac-
turer’s protocol of Allplex™ 2019-nCoV assay kit (Seegene, Seoul, 
Korea). RT was first carried out for 20 min at 50 ◦C and the PCR was 
performed for 15 min at 95 ◦C, followed by 45 cycles of 15 s at 94 ◦C and 
30 s at 58 ◦C. The fluorescent signal was measured every cycle with 
CFX96™ Real-Time System (Bio-Rad, CA, USA). Based on Ct values (i.e. 
threshold cycle) determined by built-in system software, the diagnostic 
decision was made on each clinical sample. 
3. Results and discussion 
3.1. Overall procedure of the NESBA for SARS-CoV-2 detection 
The overall procedure of the COVID-19 diagnosis based on the 
NESBA is illustrated in Fig. 1. The workflow consists of four sequential 
steps as follows: i) collection of clinical specimens (~3 min), ii) 
extraction of viral RNA (15 min), iii) NESBA assay for E and N genes of 
SARS-CoV-2 gRNA (30 min), and iv) decision making based on assay 
results (Fig. 1(a)). The target regions of E and N genes were set based on 
SARS-CoV-2 genome map (GenBank accession number: MN908947) 
(Fig. 1(b)) and the NESBA reaction mainly consists of four inter-
connected reactions: i) formation of T7 promotor-containing double- 
stranded DNA, ii) nicking and extension chain reaction-based expo-
nential amplification of T7DNAs, iii) transcription-mediated RNA 
amplification, and iv) molecular beacon probe-based fluorescent 
enhancement (Fig. 1(c)). Particularly, to enable the exponential ampli-
fication of T7DNAs, the NESBA primer sets for E and N genes were 
designed to contain nicking recognition sequence (NRS) at the 5’ end of 
the primer sets and T7 promoter sequence for reverse NESBA primers. 
In the presence of SARS-CoV-2 gRNA, the reverse NESBA primer 
binds to the target RNA and is reverse-transcribed to produce cDNA/ 
RNA hybrid by reverse transcriptase (RTase). After RNA degradation by 
RNase H, forward NESBA primer binds to the cDNA and is extended to 
form T7DNA by the intrinsic DNA polymerase activity of the RTase. The 
nicking enzyme then recognizes the double-stranded NRSs (dsNRSs) of 
the T7DNA and cleaves the site four bases downstream to the dsNRS, 
where the nicking and extension chain reaction with displacement is 
repeated to generate a large amount of templates for the counterpart 
primers. After extension of the counterpart primer, the dsNRS is also 
formed to initiate another cycle, which provides templates for the 
opposite primers. In this way, the nicking and extension chain reaction 
repeatedly proceeds to exponentially amplify the T7DNAs. 
The amplified T7DNAs produce a large amount of RNA amplicons 
utilizing T7 RNA polymerase-catalyzed transcription, whose sequence is 
complementary to MB. This leads to the opening of MBs and concomi-
tant fluorescent signal enhancement from FAM. Importantly, the RNA 
amplicons also serve as a template for the production of T7DNAs, 
accelerating the amplification. 
3.2. Feasibility of the NESBA for SARS-CoV-2 detection 
We first validated the feasibility of the NESBA by conducting the 
reactions for E and N genes of SARS-CoV-2 gRNA and monitoring the 
real-time fluorescent signals produced from gene-specific MBs binding 
to the amplified RNA amplicon under various combinations of key re-
action components (Fig. 2(a) and (b)). The highly enhanced fluorescent 
signal was observed when all key components including the NESBA 
primer set and NE together with target gRNA were applied (curve 1), 
whereas no fluorescent signal was observed without target gRNA (curve 
2). In the absence of one or more key components, the reactions also 
produced fluorescent signal to some extent from the target, but the 
signal intensity was quite lower than that from the complete NESBA 
reaction because the reactions are not able to bring about the nicking 
and extension chain reaction (curves 3, 5, and 6). We additionally 
conducted agarose gel electrophoresis analysis for the products obtained 
from the NESBA reactions to further support the fluorescent results 
(Fig. 2(c) and (d)). For this analysis, we priorly conducted the RT-PCR 
reactions by employing a NESBA, NESBA/NASBA combined, or 
NASBA primer set to obtain the possible T7DNA intermediates products, 
which include T7DNA (NESBA) having the nicking site at both ends, 
T7DNA-1 (NESBA) and T7DNA-2 (NESBA) having the nicking site at 
only one end, and T7DNA (NASBA) without any nicking site. The pro-
duced four T7DNA intermediate products were then used as markers 
(M1-M4) for the analysis of the NESBA reaction products. As a result 
presented in Fig. 2(c) and (d), only lane 1 containing all NESBA com-
ponents (target gRNA, a NESBA primer set, NASBA enzyme cocktail, and 
NE) showed the bands corresponding to the three key intermediate 
products of the NESBA reaction including T7DNA (NESBA) (M1), 
T7DNA-1 (NESBA) (M2), and T7DNA-2 (NESBA) (M3) while none of 
them was observed without target gRNA (lane 2). On the other hand, the 
conventional NASBA reaction using a NASBA primer set correctly pro-
duced the key intermediate T7DNA product without any nicking site at a 
slightly lower position only in the presence of target gRNA (lane 3). 
When NE was additionally added to the NASBA reaction, there was no 
change for the T7DNA product band (lane 5), indicating that a NESBA 
primer set is essential to produce the intermediate T7DNA products 
containing the nicking site. Very importantly, the T7DNA product bands 
obtained from the complete NESBA reaction (lane 1) were much more 
intense than those from the NASBA reaction (lane 3) and the incomplete 
NESBA reactions omitting either a NESBA primer set (lane 5) or NE (lane 
6). All these results clearly confirm that the NESBA reaction is properly 
initiated by target gRNA and both a NESBA primer set containing 
nicking site at 5’ end and NE are quite essential to achieve the highly 
enhanced amplifying capability of the NESBA reaction, as envisioned in 
Fig. 1(c). 
3.3. Sensitivity of the NESBA for SARS-CoV-2 detection 
To maximize the performance of the NESBA reaction, the NESBA 
primer set was optimized by monitoring real-time fluorescent signals 
produced from the assay reactions using differently designed NESBA 
primer sets. As presented in Figs. S2(a) and (b), E(I)- and N(I)-NESBA 
primer sets resulted in the most efficient amplification for E and N 
genes of SARS-CoV-2 gRNA and were employed for further experiments. 
To determine the sensitivity of the proposed strategy, SARS-CoV-2 
gRNA at varying concentrations in the range from 5 × 10− 1 to 5 ×
105 copies/μL was subjected to the reaction and the produced fluores-
cent signals were measured. As shown in Fig. 3(a) and (c), the threshold 
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Fig. 1. The overall procedure of the COVID-19 diagnosis by NESBA. (a) The workflow of the COVID-19 diagnosis. (b) The SARS-CoV-2 genome map (GenBank 
accession number: MN908947) and target regions of the NEBSA. (c) Schematic illustration of the NESBA for target RNA detection. The arrow indicates the 3′ end of 
the nucleic acid strand. 
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time (Tt), defined as the time when the fluorescent signal reaches the 
threshold (100 a.u.), decreased in proportion to the increasing SARS- 
CoV-2 gRNA concentration (CSARS-CoV-2). Notably, the lowest target 
concentration (0.5 copies/μL) yielded the threshold fluorescent signal 
within 30 min for both E and N genes. When the Tt values were plotted 
against the logarithm (log) of CSARS-CoV-2, excellent linear relationship 
was obtained for E gene (Tt = - 3.514 log (CSARS-CoV-2) + 27.605, R2 =
0.996) and N gene (Tt = - 4.216 log (CSARS-CoV-2) + 33.805, R2 = 0.99), 
confirming that the NESBA reaction is quite capable of quantitatively 
detecting target gRNA in a real-time manner (Fig. 3(b) and (d)). The 
limit of detection (LOD) for E and N genes was determined to be all 0.5 
copies/μL. 
We also conducted the conventional NASBA reactions for the same 
SARS-CoV-2 gRNA samples and repeated the same procedures to 
determine the LOD of the NASBA reaction. As a result (Fig. S1), the LOD 
for E and N genes was determined to be all 50 copies/μL, which is 100- 
fold higher than that of the NESBA reaction. These results firmly confirm 
that the proposed NESBA reaction could yield much higher sensitivity 
than that of the traditional NASBA reaction. Furthermore, the LOD of the 
NESBA reaction is lower than those of qRT-PCR and other isothermal 
nucleic acid amplification techniques (Table S2). 
3.4. Specificity of the NESBA for SARS-CoV-2 
The specificity of the NESBA reaction was next assessed by exam-
ining the time-dependent fluorescent signals produced by other types of 
human coronavirus strains such as SARS-CoV, MERS-CoV, HCoV-229E, 
HCoV-NL63, HCoV-HKU-1, and HCoV-OC43. 
As shown in Fig. 4, only the sample containing target SARS-CoV-2 
gRNA showed highly enhanced fluorescent signal for both E and N 
genes, while the nontarget samples containing other types of human 
coronavirus gRNA produced negligible fluorescent signals comparable 
to that of the blank. In the case of SARS-CoV, however, the fluorescent 
signal resulting from E gene was quite significant and not negligible. 
Fig. 2. Feasibility test of the NESBA for E 
and N genes of SARS-CoV-2 gRNA. Time- 
dependent fluorescent signals produced 
from gene-specific MBs during the NESBA 
reaction for (a) E and (b) N genes. Agarose 
gel electrophoresis image of the products 
obtained after 45 min NESBA reaction for (c) 
E and (d) N genes (1: Target gRNA + E(I) or 
N(I)-NESBA primer set + NASBA enzyme 
cocktail + NE, 2: E(I) or N(I)-NESBA primer 
set + NASBA enzyme cocktail + NE, 3: 
Target gRNA + E or N-NASBA primer set +
NASBA enzyme cocktail, 4: E or N-NASBA 
primer set + NASBA enzyme cocktail, 5: 
Target gRNA + E or N-NASBA primer set +
NASBA enzyme cocktail + NE, and 6: Target 
gRNA + E(I) or N(I)-NESBA primer set +
NASBA enzyme cocktail). The final concen-
tration of SARS-CoV-2 gRNA is 5 × 105 
copies/μL. M1-M4 are markers for band 
analysis (L: 25/100 bp mixed DNA ladder, 
M1: T7DNA (NESBA), M2: T7DNA-1 
(NESBA), M3: T7DNA-2 (NESBA), M4: 
T7DNA (NASBA). We obtained the repre-
sentative lines in (a) and (b) from the trip-
licate experiments and the reproducibility of 
the experiments were confirmed by the CV 
values for Tt in Table S5, which were all 
smaller than 5%. Tt is the time when the 
fluorescent signal reaches the threshold (100 
a.u.) and CV is calculated as (Standard de-
viation of Tt)/(Mean of Tt) × 100. The final 
concentrations of markers used for M1-M4 
are 100 nM.   
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When we analyzed the nucleotide sequence alignment for the six human 
coronaviruses with respect to the target SARS-CoV-2 (Table S3), the E 
gene of SARS-CoV was about 94% identical with that of SARS-CoV-2 and 
this high sequence homology resulted in the nonspecific signal from E 
gene of SARS-CoV. This result indicates that a single region is not 
enough and two regions are normally needed for the testing to accu-
rately identify and discriminate SARS-CoV-2 against other human 
coronaviruses. Except for the E gene of SARS-CoV having abnormally 
high sequence homology, the NESBA completely discriminated both the 
E and N genes of target SARS-CoV-2 against all the nontarget human 
coronaviruses, confirming the excellent specificity of the NESBA. 
3.5. Clinical applicability of the NESBA in COVID-19 diagnosis 
To verify its clinical applicability, the NESBA reaction was applied to 
test a large cohort of clinical samples (nasopharyngeal swab and 
sputum; n = 98) and the resulting fluorescent signals were measured. 
The samples that produce fluorescent signals that exceed the threshold, 
which is defined as background + 5SD, where the background is the 
mean fluorescent signal of the blank at 30 min and SD is the standard 
deviation of the blank, were evaluated as positive whereas those that do 
not exceed the threshold were evaluated as negative (Diao et al., 2020; 
Fotis et al., 2021; Nessler et al., 2020). 
As shown in Fig. S3, the samples that were determined as positive by 
qRT-PCR lead to higher fluorescent signals than the threshold, while the 
samples that were determined as negative by qRT-PCR lead to lower 
Fig. 3. Sensitivity of the NESBA for E and N 
genes of SARS-CoV-2 gRNA. Time-dependent 
fluorescent signals produced from gene- 
specific MBs during the NESBA reaction for 
(a) E and (b) N genes of SARS-CoV-2 gRNA at 
varying concentrations. The linear relation-
ship between Tt and logarithmic CSARS-CoV-2 
for (b) E and (d) N genes of SARS-CoV-2 gRNA 
in the range from 5 × 10− 1 to 5 × 105 copies/ 
μL, where Tt is defined as the time when the 
fluorescent signal reaches the threshold (100 
a.u.) and CSARS-CoV-2 is the concentration of 
SARS-CoV-2 gRNA.   
Fig. 4. Specificity of the NESBA for E and N 
genes of SARS-CoV-2 gRNA. Time-dependent 
fluorescent signals produced from gene-specific 
MBs during the NESBA reaction for (a) E and 
(b) N genes of SARS-CoV-2 or other types of 
human coronaviruses such as SARS-CoV, MERS- 
CoV, HCoV-HKU-1, HCoV-229E, HCoV-NL63, 
and HCoV-OC43. The concentration of SARS- 
CoV-2 gRNA and other viral RNAs is 5 × 105 
copies/μL for all seven human coronaviruses. We 
obtained the representative lines in (a) and (b) 
from the triplicate experiments and the repro-
ducibility of the experiments were confirmed by 
the CV values for Tt in Table S6, which were all 
smaller than 5%. Tt is the time when the fluo-
rescent signal reaches the threshold (100 a.u.) 
and CV is calculated as (Standard deviation of 
Tt)/(Mean of Tt) × 100.   
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fluorescent signals than the threshold and the overall results of the 
NESBA well agree with those of the qRT-PCR (Table S4). In order to 
visually compare the diagnosis results of the clinical samples, we display 
a heatmap based on the fluorescent signal intensities that correspond to 
the samples (Fig. 5). The NESBA was able to correctly identify 30 pos-
itive and 68 negative samples with 100% clinical sensitivity (95% CI 
88.43%–100.00%) and 100% clinical specificity (95% CI 94.72%– 
100%) with short turnaround time. These results show that NESBA is a 
clinically robust technique with great potential for POC application that 
could serve as a compelling alternative to the current gold standard, 
qRT-PCR in COVID-19 diagnosis (Table 1). 
3.6. Multiplex detection of the NESBA for SARS-CoV-2 
By employing spectrally distinct MBs, we finally validated the 
multiplex analytical capability of the NESBA for the simultaneous 
detection of SARS-CoV-2 E and N genes in one-pot. For this purpose, the 
FAM of N-gene specific MB (N(I)-MB) was replaced with HEX (N(I)-MB- 
HEX) which does not spectrally overlap with FAM, while the FAM of E 
Fig. 5. The heat map of the clinical sample diagnosis with the NESBA. Fluorescent signals produced from E(I)-MB and N(I)-MB at 30 min in response to gRNA of 
representative, suspicious COVID-19 patients. The heat map results indicate the fluorescent signals from 0 to 300 a.u., determining the final diagnosis decision as (a) 
positive and (b) negative based on the threshold (background + 5SD). 
Table 1 




E gene N gene E gene N gene 
Positive True 30 29 30 30 
False - - - - 
Negative True 68 68 68 68 
False - 1 - - 
Sensitivity (%) 
(95% CIc%) 




100 (88.4 to 
100) 




100 (94.7 to 
100) 
100 (94.7 to 
100) 
100 (94.7 to 
100) 
100 (94.7 to 
100)  
a The cases were confirmed as positive and negative based on the clinical 
sample analysis in Table S4. 
b The qRT-PCR was carried out using AllplexTM 2019-nCoV assay kit (Seegene, 
Seoul, Korea). 
c Confidence interval (MedCalc software, version 20.011). 
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(I)-MB was kept. As shown in Fig. 6, both E and N genes of SARS-CoV-2 
gRNA were very successfully identified by producing the intense fluo-
rescent signals in the corresponding fluorescent channels when the 
NESBA primer sets for E and N genes were applied together or separately 
while the blank sample did not produce any significant signal in both 
channels. These results clearly demonstrate that the NESBA is capable of 
simultaneously identifying several different regions of target nucleic 
acids in a multiplexed manner. 
4. Conclusion 
In this study, we developed the NESBA system for rapid, accurate 
COVID-19 diagnosis with simple yet ingenious design of NESBA primer 
set. The NESBA primer set, which possesses the NRS at the 5′-end of 
conventional NASBA primers, exerts the nicking enzyme-aided expo-
nential amplification and significantly enhanced the detection sensi-
tivity. With NESBA, we assayed SARS-CoV-2 gRNA within 30 min in a 
sample-to-detect manner and achieved high detection sensitivity (0.5 
copies/μL (= 10 copies/reaction) for E and N genes and specificity. 
Through tests of a large cohort of clinical samples (nasopharyngeal 
swab and sputum; n = 98) and comparison with qRT-PCR results, its 
clinical validity was also demonstrated with 100% clinical sensitivity 
(95% CI 88.4%–100.00%) and 100% clinical specificity (95% CI 94.7%– 
100%). Moreover, we successfully applied the NESBA to multiplex 
detection of E and N genes of SARS-CoV-2 gRNA in one-pot by 
employing spectrally distinct MBs. Overall, the developed method is 
highly convenient and more advantageous compared to previous 
detection systems for COVID-19 in terms of probe design, assay pro-
cedure, and detection performances including clinical accuracy and 
multiplex capability. Therefore, the NESBA would play a central role in 
clinical and on-site COVID-19 diagnostics as a compelling alternative to 
qRT-PCR. Furthermore, it would serve as a universal diagnostic platform 
to upcoming or existing infectious diseases due to intrinsically flexible 
probe design. 
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